



New Insights in Radiotherapy

Guest Editor:

Dr. Carlos Martinez-Campa

Department of Physiology and
Pharmacology, University of
Cantabria, Santander, Spain

Deadline for manuscript
submissions:

closed (25 January 2022)

Message from the Guest Editor

This Special Issue “New Insights in Radiotherapy” will include reviews and original research on advances in radiation cancer treatments. We encourage scientists to submit manuscripts addressing any of the different aspects of this therapeutic option, such as: improvements in clinical strategies to enhance radiotherapy efficacy, new surgery and imaging techniques (e.g., MR-linacs or SBRT), the development of new radiosensitising agents (molecules, nanoparticles) able to increase the effect of radiation in tumour cells and/or radioprotector agents able to decrease the adverse effects on normal tissues. Novel insights in the identification of the molecular targets involved in the response to radiation, including cell survival and proliferation signalling pathways, the identification of mechanisms of tumour resistance to ionising radiation, the role of miRNAs and lncRNAs, the identification of changes in the transcriptome of both irradiated healthy and cancerous cells, or studies combining radiation and chemotherapy are of particular interest for this issue. Original investigations and comprehensive review articles are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)